CSRxP Praises President-Elect’s Commitment to Lower Prescription Drug Prices

“We are encouraged to see the president-elect is ready to take action. We look forward to working with the new Administration and the new Congress to find solutions to fix the broken prescription drug market, and to help make life-saving medications more affordable for the patients who need them.”

Read more

CSRxP Blasts Novo Nordisk’s Plans for Prescription Price Hikes

Based on Novo Nordisk’s announcement, it is clear that the company will continue to hike insulin prices, despite the financial burdens already facing patients. “The prescription drug market is clearly broken when limiting yearly price increases to ten percent is considered bighearted,” said John Rother.

Read more

Prices Skyrocket for Drugs Used to Treat Some of the Most Prevalent Health Conditions Facing Americans

“Millions of Americans rely on prescription drugs to get and stay healthy. The challenges of dealing with a health condition are only made worse when pharmaceutical companies take advantage of patients and raising prices where they see an increased market opportunity,” said CSRxP Executive Director John Rother.

Read more

American Diabetes Association calls on Congress to hold hearings on insulin prices

The American Diabetes Association’s board of directors is calling on Congress to hold hearings to investigate dramatic increases in insulin prices and to take action to ensure that people have affordable access to the essential drug.

Read more